Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Section 6 of 6

References

173 sources

  1. Abivax ABX464-101 protocol (2018) (opens in a new tab)
  2. Abivax ABX464-101 statistical analysis plan (2018) (opens in a new tab)
  3. Abivax ABX464-102 protocol (2022) (opens in a new tab)
  4. Abivax ABX464-102 statistical analysis plan (2022) (opens in a new tab)
  5. Abivax ABX464-103 protocol (2020) (opens in a new tab)
  6. Abivax ABX464-103 statistical analysis plan (2021) (opens in a new tab)
  7. Abivax ABX464-104 protocol (2022) (opens in a new tab)
  8. Abivax ABX464-104 statistical analysis plan (2023) (opens in a new tab)
  9. Abivax ABX464-105 protocol (2024) (opens in a new tab)
  10. Abivax ABX464-105 statistical analysis plan (2025) (opens in a new tab)
  11. Abivax ABX464-106 protocol (2024) (opens in a new tab)
  12. Abivax ABX464-106 statistical analysis plan (2025) (opens in a new tab)
  13. Abivax ABX464-902 protocol and statistical analysis plan (2021) (opens in a new tab)
  14. Abivax corporate presentation (2026) (opens in a new tab)
  15. Abivax first half 2026 results announcement (2026) (opens in a new tab)
  16. Abivax first quarter 2026 results announcement (2026) (opens in a new tab)
  17. Abivax Form 20-F (2026) (opens in a new tab)
  18. Abivax full year 2025 results announcement (2026) (opens in a new tab)
  19. Abivax obefazimod web page (opens in a new tab)
  20. Abivax press release, 2026 corporate outlook (2026) (opens in a new tab)
  21. Abivax press release, ABTECT induction results (2025) (opens in a new tab)
  22. Abivax press release, ABTECT maintenance Part 2 results (2026) (opens in a new tab)
  23. Abivax press release, ABTECT maintenance results (2026) (opens in a new tab)
  24. Abivax press release, ABX464-102 authorization (2018) (opens in a new tab)
  25. Abivax press release, commercial leadership appointments (2026) (opens in a new tab)
  26. Abivax press release, DDW 2026 presentations (2026) (opens in a new tab)
  27. Abivax press release, ECCO 2026 presentations (2026) (opens in a new tab)
  28. Abivax press release, patient-reported outcomes from ABTECT induction (2025) (opens in a new tab)
  29. Abivax press release, phase 2a 12-month maintenance data (2019) (opens in a new tab)
  30. Abivax press release, phase 2a Gastroenterology publication (2021) (opens in a new tab)
  31. Abivax press release, phase 2a induction results (2018) (opens in a new tab)
  32. Abivax press release, phase 2a six-month maintenance data (2019) (opens in a new tab)
  33. Abivax press release, phase 2a three-year maintenance data (2021) (opens in a new tab)
  34. Abivax press release, phase 2a two-year maintenance data (2020) (opens in a new tab)
  35. Abivax press release, pre-NDA interaction with the FDA (2026) (opens in a new tab)
  36. Abivax press release, UEG late-breaking AT-IR subgroup data (2025) (opens in a new tab)
  37. Abivax press release, UEG late-breaking safety data (2025) (opens in a new tab)
  38. Abivax press release, UEG Week 2026 presentations (2026) (opens in a new tab)
  39. Abivax prospectus supplement (2026) (opens in a new tab)
  40. Adamina et al. (2026) (opens in a new tab)
  41. Ahuja et al. (2026) (opens in a new tab)
  42. Ananthakrishnan et al. (2024) (opens in a new tab)
  43. Apolit et al. (2023) (opens in a new tab)
  44. Armuzzi et al. (2020) (opens in a new tab)
  45. Baert et al. (2026) (opens in a new tab)
  46. Barberio et al. (2021) (opens in a new tab)
  47. Barberio et al. (2025) (opens in a new tab)
  48. Bewtra et al. (2013) (opens in a new tab)
  49. Bloudek et al. (2021) (opens in a new tab)
  50. Butler and Segal (2025) (opens in a new tab)
  51. California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2025) (opens in a new tab)
  52. California Department of Health Care Access and Information Prescription Drug Wholesale Acquisition Cost Increases (2026) (opens in a new tab)
  53. California Department of Health Care Access and Information Prescription Drugs Introduced to Market (2023) (opens in a new tab)
  54. Chebli et al. (2017) (opens in a new tab)
  55. Cichewicz et al. (2023) (opens in a new tab)
  56. ClinicalTrials.gov NCT02731885 (opens in a new tab)
  57. ClinicalTrials.gov NCT02792686 (opens in a new tab)
  58. ClinicalTrials.gov NCT03093259 (opens in a new tab)
  59. ClinicalTrials.gov NCT03093259 results (opens in a new tab)
  60. ClinicalTrials.gov NCT03368118 (opens in a new tab)
  61. ClinicalTrials.gov NCT03368118 results (opens in a new tab)
  62. ClinicalTrials.gov NCT03760003 (opens in a new tab)
  63. ClinicalTrials.gov NCT03760003 results (opens in a new tab)
  64. ClinicalTrials.gov NCT04023396 (opens in a new tab)
  65. ClinicalTrials.gov NCT04023396 results (opens in a new tab)
  66. ClinicalTrials.gov NCT05032560 (opens in a new tab)
  67. ClinicalTrials.gov NCT05121714 (opens in a new tab)
  68. ClinicalTrials.gov NCT05121714 results (opens in a new tab)
  69. ClinicalTrials.gov NCT05177835 (opens in a new tab)
  70. ClinicalTrials.gov NCT05507203 (opens in a new tab)
  71. ClinicalTrials.gov NCT05507203 results (opens in a new tab)
  72. ClinicalTrials.gov NCT05507216 (opens in a new tab)
  73. ClinicalTrials.gov NCT05507216 results (opens in a new tab)
  74. ClinicalTrials.gov NCT05535946 (opens in a new tab)
  75. ClinicalTrials.gov NCT06456593 (opens in a new tab)
  76. ClinicalTrials.gov NCT07453784 (opens in a new tab)
  77. CMS fact sheet, negotiated prices for initial price applicability year 2026 (2024) (opens in a new tab)
  78. CMS fact sheet, third cycle of negotiation (2026) (opens in a new tab)
  79. CMS MIPS Quality ID 275 specification (2025) (opens in a new tab)
  80. CTIS.eu 2022-500537-84-01 (opens in a new tab)
  81. CTIS.eu 2023-505297-15-00 (opens in a new tab)
  82. CTIS.eu 2023-505299-31-00 (opens in a new tab)
  83. CTIS.eu 2023-509226-21-00 (opens in a new tab)
  84. CTIS.eu 2024-514561-20-00 (opens in a new tab)
  85. D'Haens et al. (2026) (opens in a new tab)
  86. Dadoo et al. (2026) (opens in a new tab)
  87. Danese et al. (2026) (opens in a new tab)
  88. Digestive Disease Week poster, ABTECT integrated safety (2026) (opens in a new tab)
  89. Dignass et al. (2024) (opens in a new tab)
  90. Ding et al. (2022) (opens in a new tab)
  91. Dubinsky et al. (2021) (opens in a new tab)
  92. Dulai et al. (2026) (opens in a new tab)
  93. EMA paediatric investigation plan decision P/0205/2024 (2024) (opens in a new tab)
  94. EMA paediatric investigation plan decision, March 2025 (2025) (opens in a new tab)
  95. Entyvio prescribing information (2026) (opens in a new tab)
  96. EU Clinical Trials Information System 2022-500535-36-01 (opens in a new tab)
  97. EU Clinical Trials Information System 2022-500536-11-01 (opens in a new tab)
  98. EU Clinical Trials Information System 2023-505297-15-00 (opens in a new tab)
  99. EU Clinical Trials Information System 2023-505299-31-00 (opens in a new tab)
  100. EU Clinical Trials Information System 2023-509226-21-00 (opens in a new tab)
  101. EU Clinical Trials Information System 2024-514561-20-00 (opens in a new tab)
  102. FDA draft guidance, ulcerative colitis drug development (2022) (opens in a new tab)
  103. Fumery et al. (2018) (opens in a new tab)
  104. Gisbert et al. (2026) (opens in a new tab)
  105. Gros and Kaplan (2023) (opens in a new tab)
  106. Gulati et al. (2025) (opens in a new tab)
  107. Health Research Authority research summary, ABX464 drug-drug interaction study (opens in a new tab)
  108. Heeren et al. (2026) (opens in a new tab)
  109. Holubar et al. (2009) (opens in a new tab)
  110. Honap et al. (2026) (opens in a new tab)
  111. Hracs et al. (2025) (opens in a new tab)
  112. Humira prescribing information (2025) (opens in a new tab)
  113. ICER special assessment of Entyvio to inform CMS negotiation (2026) (opens in a new tab)
  114. ICER Targeted Immune Modulators for Ulcerative Colitis final evidence report (2020) (opens in a new tab)
  115. Imuran prescribing information (2024) (opens in a new tab)
  116. Jess et al. (2007) (opens in a new tab)
  117. Katsoula et al. (2025) (opens in a new tab)
  118. Kilic et al. (2024) (opens in a new tab)
  119. Kobayashi et al. (2020) (opens in a new tab)
  120. Lanzotti et al. (2026) (opens in a new tab)
  121. Le Berre et al. (2023) (opens in a new tab)
  122. Lee et al. (2024) (opens in a new tab)
  123. Lewis et al. (2023) (opens in a new tab)
  124. Lialda prescribing information (2026) (opens in a new tab)
  125. Lichtenstein et al. (2020) (opens in a new tab)
  126. Long et al. (2020) (opens in a new tab)
  127. NCI Drug Dictionary (opens in a new tab)
  128. Ng et al. (2024) (opens in a new tab)
  129. Olén et al. (2020) (opens in a new tab)
  130. Olivera et al. (2026) (opens in a new tab)
  131. Omvoh prescribing information (2025) (opens in a new tab)
  132. Pandey et al. (2021) (opens in a new tab)
  133. Park et al. (2020) (opens in a new tab)
  134. Parra-Izquierdo et al. (2026) (opens in a new tab)
  135. Porter et al. (2020) (opens in a new tab)
  136. Remicade prescribing information (2025) (opens in a new tab)
  137. Rinvoq prescribing information (2026) (opens in a new tab)
  138. Rubin et al. (2025) (opens in a new tab)
  139. Sands et al. (2026a) (opens in a new tab)
  140. Sands et al. (2026b) (opens in a new tab)
  141. Scherrer et al. (2016) (opens in a new tab)
  142. Scherrer et al. (2017) (opens in a new tab)
  143. Seidler et al. (2026) (opens in a new tab)
  144. Shaffer et al. (2021) (opens in a new tab)
  145. Shehab et al. (2025) (opens in a new tab)
  146. Siegmund et al. (2026) (opens in a new tab)
  147. Singh et al. (2024) (opens in a new tab)
  148. Skyrizi prescribing information (2026) (opens in a new tab)
  149. Steens et al. (2017) (opens in a new tab)
  150. Stelara prescribing information (2026) (opens in a new tab)
  151. Streetwise Reports (2026) (opens in a new tab)
  152. Tazi et al. (2021) (opens in a new tab)
  153. Tilg et al. (2026) (opens in a new tab)
  154. Travis et al. (2024) (opens in a new tab)
  155. Tremfya prescribing information (2026) (opens in a new tab)
  156. Tsai et al. (2021) (opens in a new tab)
  157. Turner et al. (2021) (opens in a new tab)
  158. Uceris prescribing information (2024) (opens in a new tab)
  159. UEG Week (2025) (opens in a new tab)
  160. UEG Week poster, Study 108 three-year analysis (2026) (opens in a new tab)
  161. Vautrin et al. (2019) (opens in a new tab)
  162. Velsipity prescribing information (2025) (opens in a new tab)
  163. Vermeire et al. (2021) (opens in a new tab)
  164. Vermeire et al. (2022) (opens in a new tab)
  165. Vermeire et al. (2023) (opens in a new tab)
  166. Vermeire et al. (2025) (opens in a new tab)
  167. WHO Drug Information (2021) (opens in a new tab)
  168. Xeljanz prescribing information (2026) (opens in a new tab)
  169. Yang et al. (2014) (opens in a new tab)
  170. Yarur et al. (2026) (opens in a new tab)
  171. Zand et al. (2020) (opens in a new tab)
  172. Zeposia prescribing information (2024) (opens in a new tab)
  173. Zhdanava et al. (2024) (opens in a new tab)